xCT as a Predictor for Survival in a Population-Based Cohort of Head and Neck Squamous Cell Carcinoma

被引:0
|
作者
Nissi, Linda [1 ,2 ,3 ]
Tuominen, Sanni [4 ,5 ]
Routila, Johannes [3 ,6 ]
Huusko, Teemu [3 ,6 ]
Ketonen, Petra [4 ,5 ]
Sundvall, Maria [1 ,2 ,3 ,7 ]
Leivo, Ilmo [3 ,8 ]
Irjala, Heikki [3 ,6 ]
Minn, Heikki [1 ,2 ,3 ]
Gronroos, Tove J. [1 ,4 ,5 ]
Ventela, Sami [6 ,9 ]
机构
[1] Turku Univ Hosp, Dept Oncol, Turku, Finland
[2] Turku Univ Hosp, FICAN West Canc Ctr, Turku, Finland
[3] Univ Turku, Turku, Finland
[4] Univ Turku, Preclin Imaging Turku PET Ctr, Turku, Finland
[5] Univ Turku, Med Res Lab, Turku, Finland
[6] Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland
[7] Univ Turku, Inst Biomed, Canc Res Unit, Turku, Finland
[8] Turku Univ Hosp, Dept Pathol, Turku, Finland
[9] Univ Turku, Turku Biosci Ctr, Turku, Finland
来源
CANCER MEDICINE | 2024年 / 13卷 / 21期
关键词
CYSTEINE/GLUTAMATE TRANSPORTER; CISPLATIN RESISTANCE; CANCER-CELLS; FOLLOW-UP; FERROPTOSIS; BIOMARKER; SLC7A11; SULFASALAZINE; SUPPRESSION; RECURRENCE;
D O I
10.1002/cam4.70371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: xCT, also known as SLC7A11 (solute carrier Family 7 Member 11), is a cystine/glutamate antiporter protein that mediates regulated cell death and antioxidant defense. The aim of this study was to investigate the effect of xCT on the outcome of patients diagnosed with new head and neck squamous cell carcinoma (HNSCC). Methods: This retrospective cohort study utilized a population-based dataset, comprising all patients (n = 1033) diagnosed with new HNSCC during 2005-2015 in a population of 697,000 people. All patients (n = 585) with a tumor tissue sample available for immunohistochemical (IHC) staining were included. The follow-up rates were 97% and 81% at 3 and 5 years, respectively. Also, the specificity of the anti-xCT antibody was validated. Results: The expression level and prognostic significance of xCT were strongly dependent on tumor location. In oropharyngeal squamous cell carcinoma (OPSCC) patients, xCT expression was a significant prognostic factor for 5-year overall survival (OAS) (HR: 2.71; 95% CI 1.67-4.39; p < 0.001), disease-specific survival (DSS) (HR: 2.58; 95% CI 1.47-4.54; p = 0.001), and disease-free survival (DFS) (HR: 2.69; 95% CI 1.55-4.64; p < 0.001). Five-year survival rates for OPSCC patients with high and low levels of xCT were OAS 34% versus 62%; DSS 51% versus 73%; DFS 43% versus 73%, respectively. According to a multivariate model adjusted for age, T-class, nodal positivity, and tobacco consumption, xCT was an independent prognostic factor for 3-year survival, in which it outperformed p16 IHC. Similar associations were not observed in squamous cell carcinomas of oral cavity or larynx. Regarding treatment modalities, xCT was most predictive in HNSCC patients who received radiotherapy. Conclusions: High xCT expression was associated with poor prognosis in OPSCC. Our findings suggest that joint analysis of xCT and p16 may add significant value in OPSCC treatment stratification.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Prediction of head and neck squamous cell carcinoma survival based on the expression of 15 lncRNAs
    Zhang, Boxin
    Wang, Haihui
    Guo, Ziyan
    Zhang, Xinhai
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (10) : 18781 - 18791
  • [22] 25 Year survival outcomes for squamous cell carcinomas of the head and neck: Population-based outcomes from a Canadian province
    Tiwana, M. S.
    Wu, J.
    Hay, J.
    Wong, F.
    Cheung, W.
    Olson, R. A.
    ORAL ONCOLOGY, 2014, 50 (07) : 651 - 656
  • [23] Lymphatic and vascular invasion in oral squamous cell carcinoma: Implications for recurrence and survival in a population-based cohort study
    Spoerl, Steffen
    Gerken, Michael
    Fischer, Rene
    Mamilos, Andreas
    Spoerl, Silvia
    Wolf, Stefanie
    Pohl, Fabian
    Klingelhoeffer, Christoph
    Ettl, Tobias
    Reichert, Torsten E.
    Spanier, Gerrit
    ORAL ONCOLOGY, 2020, 111
  • [24] Lymph node ratio as a survival predictor for head and neck squamous cell carcinoma with multiple adverse pathological features
    Tsai, Ming-Hsien
    Chuang, Hui-Ching
    Chien, Chih-Yen
    Huang, Tai-Lin
    Lu, Hui
    Su, Yan-Ye
    Yang, Chao-Hui
    Lai, Chi-Chih
    Tsai, Wen-Ling
    Lin, Yu-Tsai
    Fang, Fu-Min
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (08): : 2017 - 2027
  • [25] Human Papillomavirus in Head and Neck Squamous Cell Carcinoma of Unknown Primary Is a Common Event and a Strong Predictor of Survival
    Jensen, David Hebbelstrup
    Hedback, Nora
    Specht, Lena
    Hogdall, Estrid
    Andersen, Elo
    Therkildsen, Marianne Hamilton
    Friis-Hansen, Lennart
    Norrild, Bodil
    von Buchwald, Christian
    PLOS ONE, 2014, 9 (11):
  • [26] RETROPHARYNGEAL ADENOPATHY AS A PREDICTOR OF OUTCOME IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    MCLAUGHLIN, MP
    MENDENHALL, WM
    MANCUSO, AA
    PARSONS, JT
    MCCARTY, PJ
    CASSISI, NJ
    STRINGER, SP
    TART, RP
    MUKHERJI, SK
    MILLION, RR
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1995, 17 (03): : 190 - 198
  • [27] Arterial lactate as a predictor of postoperative complications in head and neck squamous cell carcinoma
    de Souza, Suzane Pereira
    da Silva Serra, Mauricio Gomes
    Oliveira, Neyara dos Santos
    Oliveira, Marcio Campos
    de Bessa Junior, Jose
    Reis, Tercio Guimaraes
    BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, 2022, 88 : S97 - S101
  • [28] Chromosomal breakpoints in a cohort of head and neck squamous cell carcinoma patients
    Ribeiro, I. P.
    Carreira, I. M.
    Esteves, L.
    Caramelo, F.
    Liehr, T.
    Melo, J. B.
    GENOMICS, 2020, 112 (01) : 297 - 303
  • [29] Value of maspin as a predictor of outcome in patients with squamous cell carcinoma of the head and neck
    Mhawech-Fauceglia, P.
    Bonet, M.
    Dulguerov, P.
    Beck, A.
    Allal, A. S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 168 - 168
  • [30] Age is not a predictor of prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck
    Smith, Joel A.
    Virk, Sohaib
    Palme, Carsten E.
    Low, Tsu-Hui
    Ch'ng, Sydney
    Gupta, Ruta
    Gao, Kan
    Clark, Jonathan
    ANZ JOURNAL OF SURGERY, 2018, 88 (04) : E273 - E277